BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21872826)

  • 21. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia.
    Pullarkat ST; Vardiman JW; Slovak ML; Rao DS; Rao NP; Bedell V; Said JW
    Leuk Res; 2008 Nov; 32(11):1770-5. PubMed ID: 18417213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
    Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
    Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737.
    Shimada K; Tomita A; Minami Y; Abe A; Hind CK; Kiyoi H; Cragg MS; Naoe T
    Exp Hematol; 2012 Sep; 40(9):724-737.e2. PubMed ID: 22634393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytogenetic and molecular mechanisms of resistance to imatinib.
    Hochhaus A
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
    Okabe M
    Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
    Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
    Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML).
    Chomel JC; Sorel N; Bonnet ML; Bertrand A; Brizard F; Saulnier PJ; Roy L; Guilhot F; Turhan AG
    Leuk Res; 2009 Apr; 33(4):551-5. PubMed ID: 18829107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Philadelphia chromosome-positive chronic myeloid leukemia with p190(BCR-ABL) rearrangement, overexpression of the EVI1 gene, and extreme thrombocytosis: a case report.
    Balatzenko G; Guenova M; Stoimenov A; Jotov G; Toshkov S
    Cancer Genet Cytogenet; 2008 Feb; 181(1):75-7. PubMed ID: 18262061
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical characteristics of childhood leukemia with EVI1 gene and BCR/ABL gene co-expression].
    Jiang M; Li XQ; Hu D; Zhang ZQ; Yang YY; Bai LC; Jin RM
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 May; 16(5):489-93. PubMed ID: 24856998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
    Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Moiraghi B; Bengió R; Larripa IB
    Blood Cells Mol Dis; 2010 Oct; 45(3):192-6. PubMed ID: 20728382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of the EVI1 gene in chronic myelogenous leukemia in blast crisis.
    Russell M; Thompson F; Spier C; Taetle R
    Leukemia; 1993 Oct; 7(10):1654-7. PubMed ID: 8412328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Chen Z; Shao C; Wang W; Zuo Z; Mou X; Hu SJ; DiGiuseppe JA; Zu Y; Medeiros LJ; Hu S
    Leukemia; 2017 Mar; 31(3):585-592. PubMed ID: 27560111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of array comparative genomic hybridization in chronic myeloid leukemia.
    Park S; Koh Y; Jung SH; Chung YJ
    Methods Mol Biol; 2013; 973():55-68. PubMed ID: 23412783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.
    Valent P; Herndlhofer S; Schneeweiß M; Boidol B; Ringler A; Kubicek S; Gleixner KV; Hoermann G; Hadzijusufovic E; Müllauer L; Sperr WR; Superti-Furga G; Mannhalter C
    Oncotarget; 2017 Apr; 8(14):23061-23072. PubMed ID: 28416739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.
    Bavaro L; Martelli M; Cavo M; Soverini S
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.
    Kim T; Tyndel MS; Zhang Z; Ahn J; Choi S; Szardenings M; Lipton JH; Kim HJ; Kim Dong Hwan D
    Leuk Res; 2017 Aug; 59():142-148. PubMed ID: 28667884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.